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Background: It remains unclear whether beta-blockade is similarly effective in black patients 
with heart failure and reduced ejection fraction (HFrEF) as in white patients, but self-reported 
race is a complex social construct with both biologic and environmental components. The 
objective of this study was to compare the reduction in mortality associated with beta-blocker 
exposure in HFrEF patients by both self-reported race and by proportion African genetic 
ancestry.   
Methods and Results: Insured patients with HFrEF (n=1122) were included in a prospective 
registry at Henry Ford Health System.  This included 575 self-reported blacks (129 deaths, 
22%) and 547 self-reported whites (126 deaths, 23%) followed for a median 3.0 years. Beta-
blocker exposure (BBexp) was calculated from pharmacy claims, and the proportion of African 
genetic ancestry was determined from genome-wide array data.  Time-dependent Cox 
proportional hazards regression was used to separately test the association of BBexp with all-
cause mortality by self-reported race or by proportion of African genetic ancestry.  Both sets of 
models were evaluated unadjusted and then adjusted for baseline risk factors and beta-blocker 
propensity score.  BBexp effect estimates were protective and of similar magnitude both by self-
reported race and by African genetic ancestry (adjusted HR=0.56 in blacks and adjusted 
HR=0.48 in whites).  The tests for interactions with BBexp for both self-reported race and for 
African genetic ancestry were not statistically significant in any model (p>0.1 for all).  
Conclusions: Among black and white patients with HFrEF, reduction in all-cause mortality 
associated with BBexp was similar, regardless of self-reported race or proportion African 
genetic ancestry. 
 
Key words: beta-blocker; heart failure; pharmacogenomics; pharmacogenetics; genetics; 
genomics; ancestry; race; disparity 
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CLINICAL PERSPECTIVE 
 
What is new? 
• Previous research suggested racial differences in beta-blocker effectiveness for treating 
heart failure with reduced ejection fraction by self-reported race. • We re-examined beta-blocker effectiveness by self-reported race and by genetic 
ancestry to help distinguish biological differences by race (i.e., the genetic component) 
from non-biological components/correlates of race (e.g., diet, socioeconomic status, 
others). • We found that beta-blocker treatment was associated with a similar reduction in the risk 
for mortality in self-identified blacks compared to whites, regardless of genetic ancestry 
(overall proportion African genetic ancestry).  
 
What are the clinical implications? 
• This study provides strong reassurance that there is similar benefit of beta blockade in 
African-Americans with heart failure and reduced ejection fraction compared to 
Caucasian-American counterparts. 
The landmark clinical trials that established the efficacy of beta-blockers in patients with 
heart failure (HF) with reduced ejection fraction (HFrEF) predominately consisted of white 
patients (80-99%),1-6 despite evidence that black patients have higher risk for developing and 
dying from HF.7  Subgroup analyses of these pivotal trials show effect estimates that are 
consistent with treatment benefit across races (though very limited in terms of power),8,9 and 
consensus guidelines reasonably recommend beta-blocker use in all patients with HFrEF unless 
contraindicated.101   The extrapolation of clinical trial data from one patient race to another is an 
important issue because at least 29 medications (including beta-blockers) are reported to have 
racial disparities in safety or efficacy,11 and this is clearly salient in the setting of HF.121 The Beta 
Blocker Evaluation of Survival trial (BEST), which tested bucindolol in chronic HF patients, 
showed differing effects depending on race with a trend toward harm among black patients.13,14 
Moreover, some observational datasets have suggested reduced efficacy of approved beta-
blockers in black HFrEF patients.15,16   
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A complicating issue surrounding race-based analyses is that race is a subjective social 
construct associated with a myriad of demographic, socio-economic, comorbidity and treatment 
differences that can confound estimates of treatment benefit.17  Moreover, it is imperfectly linked 
to genetic ancestry, which could indicate biological bases for difference in therapeutic 
responses, both risks and benefits. There are significant data suggesting that genetic variation, 
specifically many variants that are correlated to ancestral population, may also impact beta-
blocker effectiveness or HF disease progression.18-21  Unraveling the limitations of these prior 
reports of racial disparities in beta-blocker efficacy among HF patients requires genetic ancestry 
data that can objectively and quantitatively assess ancestral background. It is particularly 
important to include genetic ancestry in racial analyses because self-reported race can 
substantially disagree with genetic ancestry, especially in genetically admixed populations such 
as in the United States. For example, self-reported blacks tend to average approximately 20% 
European genetic ancestry, but this ranges widely from near zero to majority European genetic 
ancestry.11,22
 
  To help evaluate the effectiveness of beta-blocker use in blacks, as compared 
with whites, we developed a genetic HF registry and compared the association between beta-
blocker exposure and risk for all-cause mortality between self-identified whites and blacks, and 
then also tested the beta blockers’ associations with proportion of African genetic ancestry.   
METHODS 
 
Patient Data 
The study was approved by the Institutional Review Board at the Henry Ford Health 
System, and all patients gave written informed consent prior to participation. Due to the 
sensitive nature of this research, the data, analytic methods, and study materials will not be 
made available to other researchers for purposes of reproducing the results or replicating the 
procedure. Patients for this study came from a prospective genetic registry of HF patients with 
the overall goal of discovering novel ways to better predict prognosis and response to HF 
treatments. The registry started in October 2007 and completed in March 2015 at the Henry 
Ford Health System, which is a vertically integrated health system serving the primary and 
specialty health care needs of individuals in southeastern Michigan.  The health system includes 
several hospitals, a multispecialty physician group of ~1,200 physicians, as well as an affiliated 
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insurance product (Health Alliance Plan; all subjects are members).  Patients were included in 
the HF registry if they were 18 years of age of older, insured, and met the definition for HF as 
defined by the Framingham Heart Study.23 Specifically, patients must have had at least 2 major, 
or 1 major and 2 minor, heart failure criteria present at the time of exam or documented in the 
medical record. Major criteria were paroxysmal nocturnal dyspnea or orthopnea, neck vein 
distension, rales, cardiomegaly, acute pulmonary edema, S3 gallop, increased venous pressure 
(16 cm water), circulation time (≥ 25 seconds), and hepatojugular reflux. Minor criteria were 
ankle edema, night cough, dyspnea on exertion, hepatomegaly, pleural effusion, vital capacity 
decreased 33% from maximum, heart rate ≥ 120 beats per minute. Weight loss ≥ 4.5 kg in 5 
days in response to treatment was a major or minor criterion. Patients were excluded from the 
registry if they were on dialysis or dependent on supplemental oxygen or dialysis. Detailed 
phenotypic information (e.g., demographics, physical examination, past medical history, 
laboratory values, functional status, medications) and blood samples were collected upon 
enrollment into the HF registry. Patient deaths were collected from the Social Security 
Administration Death Master File, Michigan State Division of Vital Records, and the Henry Ford 
Health System administrative data, through July 28, 2016. Only patients with HFrEF were 
included in this analysis. Patients with left ventricular ejection fraction <50% verified by 
echocardiography, nuclear stress tests, or radionuclide blood pool imaging were included in the 
primary analysis (n = 1,122).  This EF cutoff was chosen to reflect patients with systolic HF 
because the study was designed and started prior to more recent reclassifications, suggesting 
that HFrEF should be defined as a left ventricular ejection fraction ≤ 40%.24
 
  To address whether 
this could alter our findings, we performed a secondary analysis restricted to patients with left 
ventricular ejection fraction ≤ 40% (n = 794).  
Calculation of beta-blocker exposure 
Beta-blocker exposure was calculated using dose standardization and pharmacy claims 
data as previously described.15  Briefly, doses of specific beta-blockers were standardized into 
dose equivalents by the target dose used in clinical trials of HFrEF or, for beta-blockers not 
tested in HF clinical trials (e.g., atenolol), by the maximum daily dose. Specifically, these 
target/maximal daily doses were 50 mg for carvedilol, 200 mg for metoprolol (for both long-
acting and short-acting formulations), 10 mg for bisoprolol, 100 mg for atenolol, and 600 mg for 
labetalol. For example, 25 mg of carvedilol per day (i.e., 12.5 mg twice daily) was considered a 
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0.5 beta-blocker standardized dose equivalent. Carvedilol (39%) and metoprolol succinate 
(38%) were the agents most often used, but there were smaller groups of patients using 
metoprolol tartrate (18%) or another beta-blocker (4%).   
Beta-blocker exposure was then calculated by multiplying the standardized dose 
equivalent by the quantity of medication dispensed in a 6-month time block, divided by the total 
number of days in the 6-month time block. Beta-blocker exposure was calculated for each 
patient for each day of observation, and thus this method accounts for both dose and adherence 
over a rolling period of time (6 months). For example, if a patient was prescribed 12.5 mg of 
carvedilol twice daily and had picked up their prescription from the pharmacy so that there was 
continuous availability over the previous 6 months, then their calculated beta-blocker exposure 
would be 0.5. We have previously demonstrated that this approach for calculating beta-blocker 
exposure is superior to a single time point and dichotomous classification of beta-blocker 
exposure (e.g., discharge medication status), in terms of correlation to heart rate and death or 
hospitalization.25
 
   
Genotyping & Genetic Ancestry Analysis 
Blood samples were collected at enrollment into the HF registry and were immediately 
processed and stored at -70°C.  Each sample was genotyped using the Axiom® Biobank array 
(Affymetrix), which includes the following ~600K genetic variants: 1) ~300K genome-wide 
variants with minor allele frequencies >1%, 2) ~250K low frequency (<1%) coding variants from 
global exome sequencing projects, and 3) an additional ~50K variants to improve African 
ancestry coverage (Yoruba in Ibadan, Nigeria [YRI] booster). The proportion of West African 
genetic ancestry (heretofore referred to as African ancestry) in each patient was estimated 
using ANCESTRYMAP2.0.2624
 
   Briefly, the software program uses a Hidden Markov Model to 
combine data across unlinked single nucleotide polymorphisms and incorporates information 
from many neighboring markers to infer ancestry.  
Statistical Analysis 
Continuous baseline variables were summarized by the mean ± standard deviation and 
compared by self-reported race with two-sample Student’s t-tests. Continuous baseline 
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variables that were not normally distributed were compared by self-reported race using the two-
sample Mann-Whitney test. Categorical baseline variables were summarized by counts and 
percentages and compared by self-reported race using χ2 tests, or Fisher’s exact tests when 
appropriate. Time-dependent Cox proportional hazards regression models were used to assess 
the relationship of beta-blocker exposure with the primary end point of all-cause mortality. Beta-
blocker exposure was modeled as a continuous variable with a daily value ranging from 0 
(pharmacy claims indicated that no beta-blocker was available to the patient on any day 
throughout the 6 months preceding that day) to 1 (pharmacy claims indicated that target doses 
of beta-blocker were available to the patient on every day throughout the 6 months preceding 
that day). Since beta-blocker exposure was modeled as a continuous variable, the hazard ratios 
for the association between beta-blocker exposure and all-cause mortality were scaled as zero 
exposure (0) vs target exposure (1). Beta-blocker exposure was only dichotomized when 
plotting survival curves (high exposure defined as ≥ 50th percentile and low exposure defined as 
< 50th percentile).  Two separate sets of models were made, one for self-identified race 
(dichotomous variable) and another for genetic ancestry (continuous variable), i.e. both factors 
were not in models together.  The two sets of models were otherwise similar (i.e. same 
covariates and endpoints).  Interaction between either self-reported race or proportion of genetic 
African ancestry and beta-blocker exposure was tested by incorporating a multiplicative 
interaction term within the models for time to all-cause mortality (e.g., self-identified race*beta-
blocker exposure). Models stratified by self-identified race were also developed. The models 
were adjusted for the Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) risk 
score27 (excluding beta-blocker as an input variable), NT pro-BNP level, and beta-blocker 
propensity score. Beta-blocker propensity score was calculated using logistic regression of all 
variables in Table 1 with the output separated into quartiles and used as an ordinal (1-4) 
adjuster in the Cox regression models.28 For main effects, p < 0.05 was considered statistically 
significant, and for the interaction, p < 0.1 was considered statistically significant. In the 
analyses stratified by self-reported race, we estimated 80% power to detect a hazard ratio ≤ 
0.65 for beta-blocker response, which is similar to the reduction in the risk for mortality reported 
in the landmark beta-blocker clinical trials. The primary analysis of African genetic ancestry 
included genetic ancestry as a continuous variable, which was available in all subjects, and thus 
there was similar power for the analysis of African genetic ancestry and beta-blocker survival 
benefit. However, when race was stratified by African genetic ancestry <5% and >80%, subjects 
with African genetic ancestry between 5% and 80% were excluded (n = 27 self-reported whites 
and n = 165 self-reported blacks excluded). However, the estimated power only decreased 
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slightly when race was stratified by African genetic ancestry (but not when African genetic 
ancestry was used as a continuous variable) to have 80% power to detect a hazard ratio ≤ 0.63 
for beta-blocker survival benefit. All statistical analyses were performed in SAS version 9.4 
(SAS Institute, Cary, NC). 
 
RESULTS  
 The analytic cohort comprised 1,122 HF patients meeting inclusion criteria: 575 self-
reported black patients (51%) and 547 self-reported white patients (49%).  The overall group 
had a median follow-up of 1089 days (range 3 to 3516 days). There were a total of 255 deaths 
in the analysis, 129 among black patients (22%) and 126 in white patients (23%). Baseline 
characteristics overall and stratified by self-reported race are presented in Table 1. Statistically 
significant differences at baseline were present between the groups for many characteristics, 
including age, sex, HF etiology, LVEF, and atrial fibrillation. Notably, there were no significant 
differences between race groups in terms of medication exposure, specifically including 
quantified beta-blocker exposure, categorized beta-blocker exposure (none vs. any), or 
categorized ACE/ARB exposure. Genetic admixture was observed in the cohort within both race 
groups, but was more prominent in self-identified blacks (Figure 1). Self-reported whites had an 
average of 1% African genetic ancestry, while self-reported blacks had an average of 16% 
European genetic ancestry.   
Overall, the quantified beta blocker exposure metric (BBexp) varied from 0 to 100% 
across the cohort and over time. Figure 2 depicts the mean BBexp for each individual from least 
to most across the cohort.  Roughly 25% of patients had no BBexp, while 55% had intermediate 
levels of BBexp, and 20% had relatively high-intensity BBexp.  In the overall cohort, BBexp was 
associated with improved survival. Unadjusted analysis revealed BBexp hazard ratio (HR) of 
0.47 (p=0.001).  When adjusted for baseline MAGGIC score (without the BB variable input), 
NTproBNP, and race (race is not a component of MAGGIC) the BBexp continued to be strongly 
protective with an adjusted HR (aHR) of 0.49 (p=0.005). 
 
Beta Blocker Association with Time to Death by Self-Identified Race and Genetic 
Ancestry 
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We tested Cox models of BBexp on the time to death in univariable analysis and then 
analyses adjusted for baseline MAGGIC score (minus beta-blocker input).  In unadjusted 
analyses stratified by race, BBexp was strongly protective in both groups, though showing some 
numeric separation. Among white patients, BBexp HR was 0.41 (95%CI 0.22, 0.76; p=0.005), 
while in AA patients the HR was 0.55 (95%CI 0.31, 0.98 p=0.041).  Once adjusted for baseline 
risk using MAGGIC score alone, the HR in each group were more closely aligned. For whites 
the BBexp aHR was 0.45 (0.24, 0.86 p=0.016), while for AA patients the aHR was 0.54 (0.30, 
0.97 p=0.038), again statistically significant in both groups.  Formal testing for the interaction of 
race with BBexp (i.e. adding race*BBexp term in the model) was also not significant (β=0.17, 
p=0.70). The relationship of BBexp to survival, stratified by race, is presented in Table 2 and 
illustrated in Figure 3.   
We then sought to examine whether genetic ancestry, a better reflection of genetic 
differences across race (rather than self-identified race) modulated the association of BBexp 
with survival times. Specifically, we estimated proportion of African ancestry for each individual 
and then tested similar time-dependent Cox models as above, but with proportion of African 
genetic ancestry included as a numerical covariate and with interaction terms. The BBexp effect 
did not appear to differ across the spectrum of African genetic ancestry.  In models including 
BBexp, MAGGIC, and proportion African genetic ancestry, genetic ancestry was not statistically 
significant (p=0.77), and the BBexp effect estimate was similar to the above (aHR=0.50, 
p=0.002).  Formal testing with interaction term (BBexp*ancestry) was also not statistically 
significant (p=0.71).  To better illustrate this lack of impact of African genetic ancestry on beta 
blocker effectiveness, if the BBexp HR is tabulated using a proportion African genetic ancestry 
of <5% vs. >80%, the unadjusted HR generated are 0.70 and 0.72, respectively. A comparison 
of hazards ratios for high versus low beta-blocker exposure in each race category is presented 
in Table 3. 
 
Sensitivity Analyses 
We performed several secondary analyses to assess whether our results were impacted 
by certain potential confounders or classification schemes.  First, since this was an 
observational study, confounding by indication or disease severity is always a concern.  The 
primary analysis plan included adjustment for baseline risk by using a validated clinical risk 
score (MAGGIC).  To supplement this, we additionally tested models adjusted for baseline 
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NTproBNP levels and propensity for beta-blocker use.  In terms of overall beta-blocker effect, 
when including propensity as the only covariate, the BBexp effect remains very consistent with 
the unadjusted overall analysis (aHR of 0.50, p=0.002).  The results were also similar in models 
adjusted for MAGGIC, Race, NTproBNP, and propensity (Table 2).  Importantly, in the full 
model the race*BBexp interaction remains insignificant (β=0.21, p=0.64), race was not a 
significant predictor of outcome, and in the race-stratified models the BBexp aHR were relatively 
similar (BBexp aHR 0.48 for whites and 0.56 blacks) with the estimates for each race group 
indicating a strong protective association.   
To address potential concerns regarding the fact that EF<50% was part of the inclusion 
criteria (as opposed to ≤40%), we performed additional analyses restricted to those patients 
with LV ≤40%.  Among the 1122 total subjects, 794 had EF ≤40% (n=370 white patients and 
n=424 black patients).  In these subgroups, the BBexp HR was 0.58 (p=0.14) and 0.59 (p=0.09) 
for whites and blacks, respectively.  In the full model of all patients with EF ≤40% (n= 717) 
adjusted for MAGGIC, race, and race*BBexp interaction, the BBexp HR was 0.61 (0.38, 0.98) 
p=0.040 and the interaction was not significant (p=0.78)   
 
DISCUSSION 
Definitive evidence for the efficacy of beta-blockers in blacks with HFrEF will likely never 
be obtained since the pivotal trials did not include a sufficient number of such participants and 
further randomized trials would likely be deemed unethical.  While the preponderance of 
evidence suggests a strong benefit, this prospective, observational study extends prior studies 
by both using self-reported race as a potential marker of a cluster of factors that differ and 
genetic ancestry as a quantifiable and objective biological construct. For example, if we had 
found a significant difference in beta-blocker response by self-reported race and not genetic 
ancestry, then that could suggest that the difference is likely due to socio-cultural differences 
rather than biologic. The fact that we found similar reductions in mortality stratified by self-
reported race (representative of biologic + socio-cultural effects) and genetic ancestry 
(representative of only biologic effects) is reassuring that beta-blockers are equally effective in 
white and black patients.  We found a marked reduction in mortality associated with beta-
blocker treatment that was similar in blacks and whites, regardless of race or genetic ancestry. 
Compared to the landmark trials for HF-approved beta-blockers, our study includes roughly the 
same number of black patients (n = 575) as the number of black patients in the MERIT-HF, US 
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Carvedilol Trial, COPERNICUS, and CIBIS-II combined (n = 546). The BEST trial of the non-
FDA approved bucindolol included 627 black patients, but treatment with bucindolol trended 
toward increased all-cause mortality in the black patients and a significant test for interaction of 
treatment benefit with patient race, further supporting the importance of this race-stratified 
analysis.  This study is the first to examine this issue via quantified genetic ancestry, which can 
potentially offer a more granular view of the biologic portion of race. Previous studies on the 
genetic differences in beta-blocker response have relied on candidate gene approaches, 
particularly candidate polymorphisms affecting adrenergic activity.29 Adverse genetic 
polymorphisms in the adrenergic system that are associated with decreased beta-blocker 
response are most frequent in blacks. The strength of our approach using whole-genome 
ancestry informative markers is that it captures ancestral variation across the entire genome, 
and it accounts for population substructure, a well-known phenomenon that confounds genetic 
association studies.30
Our data provide additional insight in the context of prior literature.  Our findings are 
similar to previous observational studies investigating racial differences in beta-blocker 
response in HF patients
     
16 which found protective, though non-significant, hazard ratios for 
mortality, similar to the clinical trial data for carvedilol and metroprolol succinate in blacks.  Our 
data show a significant benefit in blacks, and add a major advantage compared to previous 
observational studies, in that we utilized time-dependent quantified beta blocker exposure 
calculated from pharmacy claims.  This method is a far more granular and sensitive way of 
quantifying drug exposure (accounts for adherence, dose variability, and changes over time) 
compared with dichotomized baseline classification schemes, which were usually used in the 
previous studies.  Our data do contrast with the BEST trial findings, as well as our previous 
retrospective study,15 which yielded a statistically significant race interaction for beta-blocker-
associated benefit (i.e., increased beta-blocker benefit in whites compared to blacks for the 
composite endpoint of all-cause mortality plus hospitalization).  Given the totality of data, the 
BEST findings seem most easily explained as an agent-specific effect, since several studies 
with the other beta-blocking agents concur with our current observations.31,32  The contrast with 
our previous data is most likely due to differences in the endpoint used.  Our previous work 
utilized a composite endpoint including hospitalization, and indeed when examining our previous 
data the differences between racial groups was driven primarily by hospitalization.15  All-cause 
mortality alone (used in this prospective study) may be a better endpoint than the composite 
endpoint of all-cause mortality + hospitalization (used in our previous, retrospective study) for 
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evaluating beta-blocker efficacy. Hospitalization of heart failure patients is influenced by factors 
that are unrelated to beta-blocker efficacy more than all-cause mortality, such as patient refusal, 
lack of available beds, the number of cardiologists, whether the patient came to the hospital 
from home or a skilled nursing facility, and even the day of the week.33-36 Ultimately, 
hospitalization is the discretion of the treating physician in the emergency room or clinic.  Beta-
blockers decreased the risk of hospitalization in the landmark clinical trials, but as noted 
previously, the enrollment of African-Americans in the landmark clinical trials was extremely low. 
Recent data shows that hospitalization rates significantly differ by race,34
An additional strength of this study was the inclusion of genetic ancestry to explore more 
biologically-based mechanisms of potential racial differences in beta-blocker effectiveness. This 
is an important consideration because of the known and significant genetic admixture in the 
United States,
  and thus inclusion of 
hospitalization in the endpoint may confound the results in race-stratified analyses such as this 
study. 
17 as well as the complexity of self-identified race as a social construct. The 
availability of genetic ancestry can help differentiate true inherited differences versus the wide 
range of environmental factors that are associated with self-identified race, such as 
socioeconomic status, diet, health care quality and accessibility, all of which can make attempts 
to understand the underlying cause of race disparities in health outcomes very difficult.37  It is 
important to interrogate the role of genetic ancestry because socioeconomic factors do not fully 
explain the critical race disparities in HF outcomes,38  and to try to quantify potential genetic and 
biologic effects.  For example, African genetic ancestry is associated with poorer diastolic 
function parameters in HF patients.39
 
  Consistent with the literature, substantial genetic 
admixture was observed in our patient population, and despite the potential for differences in 
outcomes in self-reported race versus genetically defined ancestry, the reduction in the risk for 
mortality from beta-blockers in our study was mostly similar across the entire spectrum.  The 
fact that even quantified African genetic ancestry proportion, a granular marker of genetic race, 
was also not associated with differences in beta blocker benefit provides some additional 
reassurance of equal effectiveness in blacks.  
Limitations 
Our study should be interpreted in the context of the following potential limitations. While 
an observational study can never definitively assess absolute efficacy such as in a clinical trial, 
Au
th
or
 M
an
us
cr
ip
t
 This article is protected by copyright. All rights reserved 
we have taken great care to adjust for potential confounders.  We sought to mitigate 
confounders inherent in observational study design by adjusting with several methods, including 
a comprehensive and previously validated clinical score, a biomarker, and a beta-blocker 
propensity score.  Supporting our external validity is that the beta-blocker benefit estimates 
were similar to those expected from clinical trials, and overall were statistically significant. 
Another limitation of our study was that beta-blockers approved specifically for HF (i.e., 
carvedilol, metoprolol succinate, and bisoprolol) were not distinguished from other beta-
blockers. However, of the patients that were taking beta-blockers at baseline, the vast majority 
(78%) were taking HF-approved agents; the most frequent non-approved agent being 
metoprolol tartrate (18%), and only 4% of patients taking some other beta blocker. Despite 
inclusion of other beta-blockers and low beta-blocker treatment rate, an advantage of this 
observational study design is that it more closely represents current, real-world clinical practice 
than the older randomized controlled trials. Moreover, a range of beta-blocker treatment (from 
zero, to low, to target exposure) allows analysis of beta-blocker benefit, which would not be 
possible if all patients were treated with target doses of beta-blockers.” Even with inclusion of 
other beta-blockers, our results are reassuring since overall the beta blocker survival benefit 
was statistically significant in both groups and of a magnitude which approximates the findings 
from randomized trials of approved beta-blocking agents. Finally, our data is from insured 
patients in a single health system, so while our service population is diverse and reflects the 
greater regional population,40
 
 the fact that all patients had insurance and access to care may 
somewhat limit the generalizability. 
Conclusions 
 Our prospective, observational study demonstrates that beta-blocker-associated 
reduction in the risk for mortality in HFrEF patients is similar between self-reported black race 
and genetically assigned African race, as compared with whites.  We further demonstrate that 
the overall proportion African genetic ancestry, defined by genome-wide ancestry informative 
markers, does not modify the beta-blocker benefit.  These data lend further credence to current 
guidelines that recommend beta-blocker use in all HFrEF patients, reassuring patients and 
providers that black HFrEF patients are likely deriving similar benefit from beta-blocker 
treatment. These findings are not suggestive of genetic mechanisms meaningfully impacting 
beta blocker effectiveness relative to race. 
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Table 1. Baseline characteristics overall and stratified by both self-reported race and proportion of African genetic ancestry. 
Characteristic Overall 
(n = 1122) 
Black 
(n = 575) 
51% 
White 
(n = 547) 
49% 
*p >80% African 
genetic ancestry  
(n = 410) 37% 
<5% African 
genetic ancestry 
(n = 520) 46% 
†p  
Female 394 (35.1%) 231 
(40.2%) 
163 
(29.8%) 
<0.001 171 (41.7%) 153 (29.4%) <0.001 
Age (years) 67.5 ± 11.9 64.4 ± 
12.1 
70.8 ± 
10.8  
<0.001 63.8 ± 11.8 70.7 ± 10.8 <0.001 
Left ventricular ejection 
fraction (%) 
34.7 ± 11.1 33.4 ± 
11.5  
36.1 ± 
10.5  
<0.001 32.7 ± 11.3 36.1 ± 10.4 <0.001 
Ischemic etiology 494 (44.0%) 192 
(33.4%) 
302 
(55.2%) 
<0.001 124 (30.2%) 295 (56.7%) <0.001 
Hypertension 977 (88.91%) 530 
(92.2%) 
467 
(85.4%) 
<0.001 383 (93.4%) 442 (85.0%) <0.001 
Chronic obstructive 
pulmonary disease 
246 (21.9%) 118 
(20.5%) 
128 
(23.4%) 
0.244 87 (21.2%) 121 (23.3%) 0.456 
Chronic kidney disease 251 (22.4%) 158 
(27.5%) 
93 (17.0%) <0.001 123 (30.0%) 84 (16.2%) <0.001 
Atrial fibrillation 311 (27.7%) 113 
(19.7%) 
198 
(36.2%) 
<0.001 76 (18.5%) 188 (36.2% <0.001 
Stroke/transient ischemic 
attack 
140 (12.5%) 74 (12.9%) 66 (12.1%) 0.684 53 (12.9%) 60 (11.5%) 0.520 
Diabetes 462 (41.21%) 260 202 0.005 189 (46.1%) 193 (37.1%) 0.006 
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(45.2%) (36.9%) 
Body mass index (kg/m2 31.1 ± 7.3 ) 31.4 ± 7.6 30.8 ± 7.1 0.198 31.3 ± 7.7 30.8 ± 7.1 0.301 
Systolic blood pressure 
(mmHg) 
129 ± 23 131.2 ± 
24.0 
126.6 ± 
21.7 
0.001 131.7 ± 24.2 125.9 ± 21.5 <0.001 
Heart rate (beats per 
minute) 
71.2 ± 13.1 72.3 ± 
13.3 
69.9 ± 
12.8 
0.002 73.1 ± 13.6 70.0 ± 12.4 <0.001 
NT pro-BNP (pmol/L) 358 ± 380 353 ± 394  364 ± 366  0.635 354 ± 392 360 ± 363 0.812 
Serum creatinine (mg/dL)  1.28 ± 0.92 1.38 ± 
1.12 
1.18 ± 
0.60 
0.001 1.45 ± 1.27 1.17 ± 0.61 <0.001 
MAGGIC risk score (w/o 
beta-blocker) 
17.8 ± 7.3 17.3 ± 7.5 18.4 ± 7.1 0.010 17.4 ± 7.7 18.4 ± 7.2 0.045 
Beta-blocker exposure 26.6 ± 29.0 26.4 ± 
28.5 
26.7 ± 
29.6 
0.852 26.0 ± 29.0 27.0 ± 36.0 0.626 
Any beta-blocker exposure 781 (76.9%) 401 
(76.2%) 
380 
(77.6%) 
0.619 280 (74.7%) 363 (77.7%) 0.298 
ACE/ARB exposure 616 (54.9%) 331 
(57.6%) 
285 
(52.1%) 
0.066 238 (58.1%) 272 (52.3%) 0.081 
Proportion African genetic 
ancestry 
43.4 ± 44.0 83.5 ± 
20.4 
1.0 ± 6.6 <0.001 NA NA NA 
Length of follow-up (days) 1089 ± 699 1082 ± 
695  
1097 ± 
703 
0.737 1090 ± 708 1109 ± 708 0.699 
Deaths 255 (22.7%) 129 
(22.4%) 
126 
(23.0%) 
0.811 92 (22.4%) 115 (22.1) 0.906 Au
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ACE = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; MAGGIC = Meta-Analysis Global Group in 
Chronic Heart Failure risk score27
*p-value for self-reported Black vs White. Bolded p-values indicate p < 0.05. 
; NA = not applicable; NT pro-BNP = N-terminal pro b-type natriuretic peptide. 
†p-value for >80% African genetic ancestry vs <5% African genetic ancestry. Bolded p-values indicate p < 0.05. 
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Table 2. Association of beta-blocker exposure with time-to all-cause mortality in all patients and stratified by both self-
reported race and proportion of African genetic ancestry.  
 
 
Variable 
All Patients 
HR  
(95%CI) 
n = 1122 
p White 
HR  
(95%CI) 
n = 547 
p Black 
HR  
(95%CI) 
n = 575 
p <5% 
African 
genetic 
ancestry 
HR  
(95%CI) 
n = 520 
p >80% 
African 
genetic 
ancestry 
HR  
(95%CI) 
n = 410 
p 
BBexp 0.46  
(0.24, 0.89) 
0.020 0.48  
(0.25, 0.93) 
0.029 0.56  
(0.31,1.03) 
0.062 0.45 
(0.23, 
0.89) 
0.022 0.47 
(0.23, 
0.98) 
0.045 
Black  0.95  
(0.70, 1.31) 
0.765 NA    NA   NA  NA  
NTproBNP 1.47 
 (1.32, 
1.65) 
0.001 1.55  
(1.30, 1.84) 
0.001 1.38  
(1.18, 1.60) 
0.001 1.58 
(1.31, 
1.80) 
0.001 1.39  
(1.13-
1.70) 
0.002 
MAGGIC 1.11  
(1.09, 1.13) 
0.001 1.11  
(1.08, 1.15) 
0.001 1.11  
(1.07, 1.14) 
0.001 1.12 
(1.08, 
1.15) 
0.001 1.10  
(1.07, 
1.14) 
0.001 
BB Propensity  0.88 
(0.78, 0.99) 
0.038 0.76  
(0.64, 0.91) 
0.003 1.01  
(0.85, 1.19) 
0.933 0.76 
(0.63, 
0.91) 
0.003 0.97 
(0.80, 
1.18) 
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BBexp*Race  β=0.21 0.642         β=0.11 0.823   
BB = beta-blocker; BBexp = beta-blocker exposure; HR = hazard ratio; CI = confidence interval; MAGGIC = Meta-Analysis Global 
Group in Chronic Heart Failure risk score27
Bolded p-values indicate p < 0.05.  
; NA = not applicable; NTproBNP = N-terminal pro-b-type natriuretic peptide (HR scaled by 
400 units) 
Au
th
or
 M
an
us
cr
ip
t
 This article is protected by copyright. All rights reserved 
Table 3. Hazard ratios (HR) and 95% confidence intervals (CI) for high beta-blocker 
exposure (≥ 50th percentile) vs low beta-blocker exposure (< 50th
 
 percentile) in the self-
reported races and patients with <5% and >80% proportion African genetic ancestry.  
Race Category 
 Self-report Genetic 
Beta-blocker exposure White Black <5% African >80% African 
High vs low 
 
n = 516 
0.74 (0.52-1.06) 
P=0.102 
n = 543 
0.69 (0.49-0.99) 
P=0.045 
n = 490 
0.71 (0.49-1.03) 
P=0.071 
n = 388 
0.64 (0.42-0.98) 
P=0.038 
Interaction p-value  
 
p = 0.979 p = 0.992 
 
All models were adjusted for MAGGIC risk score (minus beta-blocker) and NT pro-BNP level, 
and the sample sizes were for patients with complete data available for analysis. 
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Figure Legends: 
 
Figure 1. Proportion of African genetic ancestry in the self-reported whites (left panel) 
and African-Americans (right panel).  
 
Figure 2. Mean beta blocker exposure metric (BBexp, Y axis) for each participant across 
the cohort (X axis). 
 
Figure 3. Survival curves stratified by self-reported race and high vs. low beta-blocker 
exposure. High beta-blocker exposure was defined as ≥ 50th percentile (dashed lines) and low 
beta-blocker exposure as < 50th percentile (solid lines).  Red lines are self-reported blacks and 
blue lines are self-reported whites.  
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